| BMS Stumble in HCV Trial Could Prove Gilead's Gain | | In the heat of the race for an interferon-free treatment for hepatitis C virus (HCV), Bristol-Myers Squibb Co. (BMS) stumbled over a serious safety issue in a Phase IIb trial of BMS-986094. Until it assesses the data related to the study drug, BMS is not sure what the future holds for BMS-986094. Find out the details. |  |
| Health Care & Policy |  |  | | - House bill aims for greater clinical trial transparency
The Trial and Experimental Studies Transparency Act of 2012 would require that results from all eligible clinical studies be posted on ClinicalTrials.gov within one year of the trial's completion and that trials conducted outside the U.S. in support of FDA applications be registered and reported as well. Moreover, all interventional biomedical trials on humans would have to be registered on the database before enrolling participants. Results for studies on therapies that have never been approved for any use would have to be posted within two years of trial completion. PharmaTimes (U.K.) (8/7)       - Germany allows trial of stem cell therapy for muscle regeneration
The Paul-Ehrlich-Institut, Germany's medical regulator, authorized Pluristem Therapeutics to initiate a Phase I/II clinical trial of a placenta-based stem cell treatment in 18 patients about to undergo total hip replacement. The study will evaluate the therapy's safety and efficacy in regenerating injured gluteal musculature. Globes (Israel) (8/7) - Achillion's experimental hepatitis C drug performs well in trial
The majority of patients who received Achillion Pharmaceuticals' hepatitis C drug candidate sovaprevir, plus pegylated interferon and ribavirin, demonstrated sustained viral response a month after treatment, a midstage study found. Achillion expects to release additional trial results early next year. Reuters (8/7)  | Earn 3X rewards points when you fly with The Business Gold Rewards Card from American Express OPEN. Designed to earn Membership Rewards® points faster:
• 3X points on airfare
• 2X points on advertising, gas, and shipping
• 1X points on everything else
LEARN MORE AND APPLY |
  | Company & Financial News | | | |
| Food & Agriculture | | | | - Vietnam should start biotech crop development, experts say
Vietnam should begin developing biotech plants as soon as possible, according to two agricultural experts in the country. "The cultivation in the last 16 years shows that GMPs are safe to humans and biodiversity," said Dr. Le Huy Ham of the Agricultural Institute of Genetics. Professor Vo Tong Xuan agreed and pointed to the use of biotech plants in 30 nations, including big economies such as the U.S. and China. VietNamNet Bridge (8/7) | Industrial & Environmental | | | | | News from BIO | | | | - Ship with FedEx
FedEx is now offering member companies discounts of up to 35% off select FedEx services, both U.S. and international services. The BIO program with FedEx is one of the many cost-savings programs offered by BIO through its Business Solutions program. There is no charge for BIO member companies to participate in any of the BIO Business Solutions programs -- it is a benefit of membership. Learn more about the BIO and FedEx program.
| SmartQuote | | | |  | If the highest aim of a captain were to preserve his ship, he would keep it in port forever."
--Thomas Aquinas,
Italian priest, philosopher and theologian  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Tuesday, August 07, 2012
- Monday, August 06, 2012
- Friday, August 03, 2012
- Thursday, August 02, 2012
- Wednesday, August 01, 2012
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2012 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment